University of Manitoba, Winnipeg, Manitoba, Canada.
PLoS One. 2013 Jun 6;8(6):e65156. doi: 10.1371/journal.pone.0065156. Print 2013.
This retrospective study was undertaken to evaluate the outcome of patients with stage I or II (limited stage), grade I-II follicular non-Hodgkin's lymphoma (FL) treated with radiation therapy (RT) alone as initial management.
Patients with stage I or II and pathologically confirmed WHO grade I or II FL treated initially with RT alone between 1982 and 2008 were identified from a population based cancer registry.
Forty patients with a mean age 61.3 years at diagnosis were identified. The median follow up was 6.9 years from the end of radiation therapy. Stage was I (n = 26) and II (n = 14). None had B symptoms. The Follicular Lymphoma International Prognostic Index (FLIPI) was low risk in 26 patients and intermediate risk in 5. Doses ranged from 15 Gy to 48 Gy, with a median dose of 35 Gy. All patients achieved a complete clinical response (CR). 5 and 10 year overall survival (OS) was 86% and 59%, progression free survival (PFS) 67% and 54%. Age ≥60 at diagnosis was associated with reduced OS, p = 0.029, but did not affect PFS. No other clinical features including grade or FLIPI were significant for outcomes. Local failure was uncommon occurring in 8% (3/40) although this was 21% (3/14) of all recurrences.
OS and PFS outcomes for radiation alone in limited stage low grade FL patients from this single institution study are consistent with previously published data. No predictors were prognostic for PFS. A dose of ≤35 Gy may be appropriate. In this highly selected homogeneous group the FLIPI loses discriminating ability. Local control is excellent, and a majority of patients are free of disease after 5 years.
本回顾性研究旨在评估仅接受放射治疗(RT)作为初始治疗的 I 期或 II 期(局限性)、I-II 级滤泡性非霍奇金淋巴瘤(FL)患者的治疗结果。
从基于人群的癌症登记处确定了 1982 年至 2008 年间,经病理证实为 I 或 II 级 FL 且仅接受 RT 作为初始治疗的 I 期或 II 期患者。
共确定了 40 例患者,诊断时平均年龄为 61.3 岁。中位随访时间为放射治疗结束后 6.9 年。分期为 I 期(n=26)和 II 期(n=14)。无 B 症状。滤泡性淋巴瘤国际预后指数(FLIPI)在 26 例患者中为低危,在 5 例患者中为中危。剂量范围为 15 Gy 至 48 Gy,中位剂量为 35 Gy。所有患者均达到完全临床缓解(CR)。5 年和 10 年总生存率(OS)分别为 86%和 59%,无进展生存率(PFS)分别为 67%和 54%。诊断时年龄≥60 岁与 OS 降低相关,p=0.029,但不影响 PFS。其他临床特征,包括分级或 FLIPI,对结局均无显著影响。局部失败并不常见,占 8%(3/40),尽管在所有复发患者中占 21%(3/14)。
来自单一机构研究的局限性低级别 FL 患者单独接受 RT 的 OS 和 PFS 结果与先前发表的数据一致。没有预测指标对 PFS 有预后意义。剂量≤35 Gy 可能是合适的。在这个高度选择的同质组中,FLIPI 失去了区分能力。局部控制非常好,大多数患者在 5 年后无疾病。